US 11,052,066 B2
Ultrapure tetrahydrocannabinol-11-oic acids
Mark Tepper, Newton, MA (US); Dean A. Frey, Edwardsville, IL (US); David Goeddel, Madison, WI (US); and Karl E. Reineke, Placitas, NM (US)
Assigned to Corbus Pharmaceuticals, Inc., Norwood, MA (US)
Filed by Corbus Pharmaceuticals, Inc., Norwood, MA (US)
Filed on May 29, 2019, as Appl. No. 16/425,196.
Application 15/347,059 is a division of application No. 14/546,116, filed on Nov. 18, 2014, abandoned.
Application 15/347,104 is a division of application No. 14/546,116.
Application 16/425,196 is a continuation of application No. 16/198,381, filed on Nov. 21, 2018, granted, now 10,369,131.
Application 16/198,381 is a continuation of application No. 15/698,544, filed on Sep. 7, 2017, granted, now 10,154,986, issued on Dec. 18, 2018.
Application 15/698,544 is a continuation of application No. 15/347,059, filed on Nov. 9, 2016, granted, now 9,801,849, issued on Oct. 31, 2017.
Application 14/546,116 is a continuation of application No. PCT/US2014/016050, filed on Feb. 12, 2014.
Application 15/698,544 is a continuation of application No. 15/347,104, filed on Nov. 9, 2016, granted, now 9,820,694, issued on Nov. 21, 2017.
Application 15/698,544 is a continuation of application No. 15/220,127, filed on Jul. 26, 2016, granted, now 10,085,964, issued on Oct. 2, 2018.
Application 15/220,127 is a continuation of application No. 14/546,116.
Claims priority of provisional application 61/837,743, filed on Jun. 21, 2013.
Claims priority of provisional application 61/763,630, filed on Feb. 12, 2013.
Prior Publication US 2020/0093784 A1, Mar. 26, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 9/00 (2006.01); A61P 43/00 (2006.01); A61P 37/06 (2006.01); A61P 29/00 (2006.01); A61P 25/28 (2006.01); A61P 25/04 (2006.01); A61P 25/00 (2006.01); A61P 17/02 (2006.01); A61P 17/00 (2006.01); A61P 13/12 (2006.01); A61P 11/00 (2006.01); A61P 1/16 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 9/007 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/0053 (2013.01)] 18 Claims
 
1. A pharmaceutical composition comprising a preparation of ajulemic acid and a pharmaceutically acceptable excipient, wherein the preparation of ajulemic acid comprises at least 98% (w/w) ajulemic acid or a pharmaceutically acceptable salt thereof, wherein the preparation of ajulemic acid has a Ki for the CB1 receptor (Ki CB1) ranging from 10 times to 40 times greater than its Ki for the CB2 receptor (Ki CB2), and wherein the Ki CB1 and the Ki CB2 are each determined according to a competitive radioligand binding assay with [3H]-CP55940 as the radioligand.